Ranitidine prophylaxis in acute gastric mucosal damage in critically ill pediatric patients

Crit Care Med. 1988 Jun;16(6):591-3. doi: 10.1097/00003246-198806000-00005.

Abstract

We determined the ranitidine dosage necessary to maintain gastric pH at or above 4 in 40 critically ill children. The patients were divided into four groups of ten patients each. They were treated with ranitidine in the following dosages: a) 2 mg/kg by NG tube every 12 h; b) 4 mg/kg by NG tube every 12 h; c) 0.75 mg/kg iv every 6 h; d) 1.5 mg/kg iv every 6 h. The fourth group had a higher median pH than the other groups, in spite of also having the highest risk of acute gastric mucosal damage (AGMD). Eight (80%) of ten patients in the fourth group had a pH greater than or equal to 4 or more than 80% of the study period. We recommend 1.5 mg/kg iv every 6 h for gastric acid inhibition in AGMD prophylaxis in children.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Critical Care
  • Dose-Response Relationship, Drug
  • Female
  • Gastric Acid / metabolism
  • Gastric Mucosa / drug effects*
  • Humans
  • Hydrogen-Ion Concentration
  • Infant
  • Infant, Newborn
  • Injections, Intravenous
  • Intubation, Gastrointestinal
  • Male
  • Random Allocation
  • Ranitidine / administration & dosage
  • Ranitidine / therapeutic use*
  • Risk Factors
  • Stomach Ulcer / prevention & control*

Substances

  • Ranitidine